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GVHD prophylaxis. The risk factors for TMA suggest that careful
monitoring and adjustment of TAC/SIR dosages to avoid super-
therapeutic levels is critical, particularly during ongoing GVHD.390
A NOVEL NON MYELOABLATIVE REGIMEN FOR RELATED AND UNRE-
LATED ALLOGENEIC TRANSPLANTATION OF HIGH RISK PATIENTS
WITH CHRONIC GRANULOMATOUS DISEASE (CGD)
Kang, E.M.1, Kelly, C.1, Hilligoss, D.M.1, Marquesen, M.M.1,
DeCastro, R.1, Wilder, J.2, Kwatemaa, A.N.1, Khuu, H.3,
Stroncek, D.3, Malech, H.L.1 1National Institutes of Health, Bethesda,
MD; 2National Institutes of Health, Bethesda, MD; 3National Institutes
of Health, Bethesda, MD
Allogeneic transplant can cure chronic granulomatous disease and
is increasingly being offered. However, presence of persistent unre-
sponsive severe infection deters transplant of this high-risk group,
though nonmyeloablative regimens with matched sibling donors
can succeed. In 2007 we initiated a protocol for this high-risk group
using either matched sibling or unrelated donors and show that a tol-
erance-based regimen allows for engraftment with little to no infec-
tion progression or GVHD. Using low dose Busulfan, Campath and
Rapamycin with TBI for unrelated donor recipients, we have now
transplanted 11 patients (ages 3-32); 9 with an unrelated 10/10
HLAmatched donor or a 5/6 cord blood, and 2 with a sibling donor.
We have had one primary graft failure with autologous recovery oc-
curring in the cord blood recipient who had significantly lower bu-
sulfan levels as compared to the other patients. The others all
engrafted (neutrophil count$ 500 for 3 days) by day 65 (averageday
26), showingz100% donor chimerism in the CD14/15 lineages as
measured by STR PCR. CD3 engraftment was slower with many
having less than 10%donor chimerism initially. The average number
of RBC transfusions was 2.4 units/patient with 4 patients requiring
none and 4 also not needing platelet transfusions. GVHD has been
limited to 1 patient with Grade II and 1 with Grade I of the skin.
Overall survival is 10 of 11 with 1 patient dying from non-transplant
related causes. Our longest follow up to date is 2 years in a patient
with continued full engraftment and normal immunologic function.
2 patients required a stem cell boost given without additional condi-
tioning, either for slow engraftment or unstable chimerism, and
a third patient appears to have late graft rejection with studies ongo-
ing. Most significantly, 9 of 11 patients were transplanted at the time
of an ongoing fungal or bacterial infection of lung, spine, and/or me-
ninges, often resistant to multidrug therapies. 4 patients were given
granulocyte infusions during their neutropenia. No patient had evi-
dence of infection progression, and a number showed radiologic im-
provement prior to full engraftment. Thus we have developed
a regimen with minimal GVHD, even with unrelated donors and/
or ongoing infection. Longer follow up and more patients will
help confirm our enthusiasm for this approach to treating these
high risk patients not otherwise eligible for transplant.391
NORMALISED EBV QUANTITY IN PATIENTS AFTER ALLOGENEIC HAEMA-
TOPOIETIC STEM CELL TRANSPLANTATION – BENIGN REACTIVATION,
LOCALISED AND GENERALISED EBV LYMPHOPROLIFERATIVE DISEASE
Hubacek, P.1,2, Mejstrikova, E.1, Markova, M.4, Kouba, M.4,
Kabickova, E.1, Zajac, M.2, Hornofova, L.3, Keslova, P.1, Sedlacek, P.1,
Cetkovsky, P.4 12nd Medical Faculty of Charles University and Motol
University Hospital, Prague, Czech Republic; 22nd Medical Faculty of
Charles University and Motol University Hospital, Prague, Czech Repub-
lic; 32ndMedical Faculty of Charles University andMotol University Hos-
pital, Prague, Czech Republic; 4 Institute of Haematology and Blood
Transfusion, Prague, Czech Republic
EBV remains important pathogen in patients after haematopoietic
stem cell transplantation (HSCT). Beside benign reactivation, EBV
can cause localised or generalised form of EBV associated lympho-
proliferative disease (EBV-LPD) with clinical symptoms such asfever, hepathopathy, lymphoma-like symptoms and generalised B
cell proliferation in peripheral blood.
Between I/2002 and X/2010, we tested prospectively whole blood
samples from 266 children (8,202 samples) and from 489 adults
(7,202 samples) after allogeneic HSCT. A minute number of addi-
tional tissue and body fluids samples was tested too. Retrospectively,
we tested 50 samples from 4 children who died for EBV-LPD in
2000. EBV and albumin gene were quantified using RQ-PCR and
quantity of EBV was normalised to 100,000 human genome equiva-
lents and expressed in normalised viral copies (NVCs).
In the prospective testing, EBV was detected in whole blood of
199 children (74.8%;2607 samples;median 90 normalised viral cop-
ies (NVCs) and from 301 adults (62.7%;1,749 samples;median 79
NVCs). More than 1 000 copies were detected in 62 children and
57 adults,more than 10,000 in 14 children and 13 adults. Clinical
or laboratory signs of EBV-LPD were observed in 8 children and
12 adults. Generalised EBV-LPD confirmed by detection of abnor-
mal B lymphocytes in peripheral blood was detected in 6 children
and 4 adults (mean of highest EBV 103,566 NVCs), localised form
in 2 child and 7 adults (mean of highest EBV 10,652NVCs). Despite
the rituximab treatment 3 prospectively tested adults deceased due to
treatment resistant EBV-LPD. Among retrospectively tested pa-
tients, highest quantity was between 1,165,000-11,060,500 NVCs
and the interval between the first detection of EBV and decease
was 24-91 days.
EBV can be detected in big proportion of patients after HSCT,
more frequently in paediatric population. Level of 10,000 NVCs
seems to be a good level for possible treatment and it is 100 times le-
ver than highest quantity detected patients who died of EBV-LPD.
Long lasting EBV positivity in patient with lymphomas suppose to
be EBV released from the local proliferation. Normalisation proved
to be useful approach for comparison of EBV levels in the whole
blood and in the tissues.Supported by MSMT 0021620813 and
MZ0FNM2005.392
IMPACT OF THE DISTRIBUTION AND THE EFFECT OF KIRS AND ACTIVAT-
ING KIR ON OUTCOME OF HLA-IDENTICAL SIBLING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Wei, X., Feng, Y., Sun, A., Wu, D., Tang, X. Jiangsu Institute of Hema-
tology, Suzhou, Jiangsu, China
Objective:To investigate the distribution and the effect of killer cell
immunoglobulin-like receptor (KIR) genes, as well as to explore the
impact of different activating KIRs in HLA-identical sibling hema-
topoietic stem cell transplantation (HSCT).
Methods: The genotypes of donor/recipient KIR were determined
by polymerase chain reaction-sequence specific primer (PCR-SSP)
in 40 cases of HLA-identical sibling HSCT. And a retrospective
study was carried out to analyze the outcomes of the recipients.
Results: All the patients and the donors possessed KIR
2DL1,2DL2,2DL3,3DL2,3DL3, and 95% of individuals possessed
3DL1. The frequencies of KIR2DS4, KIR2DS1, KIR3DS1,
KIR2DS5, KIR2DS2 and KIR2DS3 were 95%, 40%, 36.25%,
31.25%, 21.25%, and 20% respectively in 40 pairs of donor-recipi-
ent. The frequencies of KIR2DS4*001/002 and 2DS4*003-007 ho-
mozygotes were 55.9% and 8.8% respectively, while the frequency
for 2DS4*001/002 and 2DS4*003-007 heterozygote was 35.3%.
Among them, 62.5% of donor/recipient KIR were completely iden-
tical, while 37.5% were not. Of the non-identical KIRs,12.5% were
the recipients KIR genotype containing the donors ones,5% were
the donors KIR containing the recipients KIR, and 20% were com-
pletely different. The donor/recipient KIR completely identical
group had higher aGVHD rate and the higher incidence of III-
IVaGVHD compared with KIR not identical group (64%
vs.26.7%, P\ 0.05 and 28% vs. 0%, P\ 0.05 respectively). The
KIR not identical group had higher 2-year disease-free survival
(DFS) compared with KIR completely identical group
[(91.6767.98)% vs. (77.7869.81)%,P 5 0.3]. The incidence of re-
lapse was 19.2% when the donor without KIR2DS2, but was 0%
for the donor with KIR2DS2. Among the A/A donors, the disease-
free survival (DFS) of one year was 70% when the donor had
2DS4*003-007,and 87.5% when the donor was KIR2DS4*001/002
S296 Poster Session IIhomozygotes. The DFS of one year was 72.2% when the donors
have three or more aKIR, while if the donor had one or two
aKIR., the DFS of one year was 81.8%.
Conclusions: In HLA-identical sibling HSCT, the incidence of
aGVHD and severe aGVHD were higher in group of donor/recipi-
ent KIR completely identical.The differential expression of the num-
ber and subtype in aKIR may be related to the reduce occurrence of
disease relapse and better clinical outcome in HLA-identical sibling
HSCT.393
DAY +11 METHOTREXATE (MTX) MIGHT REDUCE THE RISK OF EN-
GRAFTMENT SYNDROME (ES) AND ACUTE GRAFT-VERSUS-HOST DIS-
EASE (GVHD) AFTER UNRELATED BONE MARROW TRANSPLANTATION
(U-BMT) WITH REDUCED-INTENSITY CONDITIONING REGIMENS
Yakushijin, K.1,2, Asakura, Y.1, Maeda, T.1, Kurosawa, S.1,
Hiramoto, N.1, Kim, S.-W.1, Mori, S.-I.1, Tanosaki, R.1, Heike, Y.1,
Takaue, Y.1, Tobinai, K.1, Fukuda, T.1 1National Cancer Center Hospi-
tal, Tokyo, Japan; 2Kobe University Hospital, Kobe, Japan
The combination of calcineurin inhibitor and short MTX is often
used for GVHD prophylaxis after allogeneic stem cell transplanta-
tion. Although day +11 MTX is sometimes omitted due to severe
complications, the benefit of day +11MTX is controversial. To eval-
uate the role of day +11 MTX, we retrospectively reviewed the med-
ical records of 142 pts with various hematological malignancies who
underwent U-BMT between 2000 and 2007 with myeloablative
(MAC, n 5 96) or reduced-intensity conditioning (RIC, n 5 46)
regimens. Patient characteristics are shown in table 1.
Table 1. Patient Characteristics
Myeloablative Reduced-intensityDose of
MTX(MAC, n596) (RIC, n546)3 doses
(n514)4 doses
(n582)3 doses
(n512)4 doses
(n534)Age median
(range)34 (22-48) 39 (9-58) 57 (19-67) 56 (10-64)Disease AML 9 32 7 13
ALL 0 12 0 1
MDS 0 14 1 7
CML 1 11 0 2
ML 1 9 3 7
other 3 4 1 4Risk group High risk 11 57 10 22
Low risk 3 25 2 12HLA status identical 12 75 12 34
mismatched 2 7 0 0Calcineurin
inhibitorCyclosporine 5 38 7 24Tacrolimus 9 44 5 10MAC consisted of 12 Gy TBI-based (n5 50) or Bu (po 16 mg/kg or
iv 12.8 mg/kg, n5 46)-based regimen, and RIC consisted of Bu (po 8
mg/kg or iv 6.4 mg/kg) in combination with either 2CdA (0.66 mg/
kg) or Flu (180 mg/m2). GVHD prophylaxis consisted of cyclospor-
ine (starting dose 3 mg/kg/day civ, target whole blood conc. 250-350
ng/ml) or tacrolimus (starting dose 0.03 mg/kg/day civ, target whole
blood conc. 10-20 ng/ml) with short MTX scheduled on day +1, +3,
+6, and day +11 (10-7-7-7 mg/m2). No pts received ATG. Among
the 142 pts, planned day +11 MTX was omitted in 26 pts (MAC; n
5 14, RIC n5 12) due to various reasons including grade 3mucositis
(n5 21), febrile neutropenia (n5 12), grade 2 jaundice (n5 4), grade
2 mucositis (n 5 3), pneumonia (n 5 1), and sepsis (n 5 1). ES was
diagnosed when pts presented with $ 2 of the following symptoms
within 96 hrs of neutrophil engraftment: (1) fever (. 38C) without
an identifiable infectious reason, (2) skin rash (. 25% of BSA) not
because of drug reactions, (3) weight gain (. 2.5% of baseline
body weight), and (4) hypoxia (SPO2\ 94%), or pulmonary infil-
trates. The median follow-up in surviving pts was 1115 days (100-
3071). In both MAC and RIC groups, median day of neutrophilengraftment, OS, NRM and relapse rate at 2 yrs were not signifi-
cantly different between the 4-dose and 3-dose groups (MAC; day
+17 vs +16, 59% vs 48%, 23% vs 25%, and 26% vs 34%, RIC; day
+18.5 vs +16.5, 45% vs 58%, 43% vs 28%, and 20% vs 19%, respec-
tively). In the MAC group, there were no significant differences of
the incidences of ES and grade II to IV acute GVHD. In the RIC
group, however, the incidence of ES was significantly lower in the
4-dose group (26% vs 58%, p 5 0.02) and the incidence of grade
II to IV acute GVHD tended to be lower (48% vs 75%, p 5 0.07)
than in the 3-dose group. In conclusion, our study suggested that
day +11 MTX might reduce the risk of ES and acute GVHD.394
EVALUATION OF MYOCARDIAL AND HEPATIC T2* MRI CHANGES IN b-
THALASSEMIA MAJOR HEMATOPOIETIC STEM CELL TRANSPLANTATION
RECIPIENTS AND THE EFFECT OF IRON OVERLOAD THERAPY
Hamidieh, A.A., Moeininia, F., Alimoghaddam, K., Jalili, M.,
Shamshiri, A., Ghavamzadeh, A. Tehran University of Medical Sciences,
Tehran, Islamic Republic of Iran
Background: Iron deposition in the heart and liver are considered to
play a central role in the long term outcome of ex-thalassemic hem-
atopoetic stem cell transplantation (HSCT) survivors. There is a lack
of correlation between heart and liver iron load. Serum ferritin and
liver iron values have almost no predictive value for cardiac iron de-
position. This study was conducted in order to assess myocardial and
hepatic iron concentrations using T2* MRI and detection of any ef-
fect of transplantation itself and chelation therapy in ex-thalassemic
patients who survived beyond six months.
Methods: In this prospective, single-center study, during 14
months, 72 major thalassemia patients candidate for allogeneic
HSCTwere evaluated for iron overload by base line liver and cardiac
T2* MRI, liver biopsy and serum ferritin and subsequently 26 pa-
tients assessed again by T2*MRI and ferritin on 6th months after
successful HSCT. Finally deferoxamine was prescribed for 12 ex-
thalassemic patients at this time according to abnormal myocardial
or hepatic T2* values. T2* MRI and serum ferritin were performed
for these patients at the end of 6th months of chelation.
Results: At baseline, the cardiac T2* was normal (. 20 ms) in 46
(63.9%) of recipients, but 69 (82%) had hepatic siderosis. The liver
T2* (mean, 4.27 6 4.22 ms) was correlated significantly with serum
ferritin levels (r-0.8, p \ 0.001), but not with myocardial values
(mean, 25.3 6 10.5 ms). Although serum ferritin increased during
six months after HSCT (mean13516 941 to 5068 6 7674 ng/ml),
the myocardial and hepatic T2* measures were not changed signifi-
cantly. After about 6 months chelation therapy in 12 ex-thalassemic
patients the liver T2* improved (5.49 6 2.74 to 4.216 2.6 ms,
p0.008) with concomitant improvement in serum ferritin (mean
50686 7674 to 24506 1824 ng/ml), but differences in ferritin levels
were not significant. The cardiac T2* measures were not improved
during this time.
Conclusion: T2*MRI is an apropriate method for baseline evalua-
tion and monitoring of chelation therapy in b-thalassemia major
HSCT recipients, where as serum ferritin level may be confusing.395
IMPORTANCE OF CYCLOSPORINE LEVELS IN THE EARLY PERIOD AFTER
REDUCED INTENSITY CONDITIONING ALLOGENEIC STEM CELL TRANS-
PLANTATION
Garcıa, I.C.1, Valcarcel, D.F.2, Pi~nana, J.L.R.1, Martino, R.B.1,
Barba, P.S.2, Novelli, S.C.1, Sureda, A.B.1, Briones, J.M.1,
Delgado, J.G.1, Brunet, S.M.1, Sierra, J.G.1, Sierra, G.J.1 1Hospital de
la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain; 2Hospital Vall
d’ Hebron, Barcelona, Barcelona, Spain
Background: The importance of cyclosporine (CsA) levels to pre-
vent acute graft versus host disease (aGVHD) has been well docu-
mented after conventional conditioning allogeneic stem cell
transplatation (Allo-SCT), but its value in the reduced intensity con-
ditioning (RIC) setting has not been evaluated. The aim of the study
